Delaby C, Teunissen CE, Blennow K, Alcolea D, Arisi I, Amar EB, Beaume A, Bedel A, Bellomo G, Bigot-Corbel E, Bjerke M, Blanc-Quintin MC, Boada M, Bousiges O, Chapman MD, Demarco ML, D'Onofrio M, Dumurgier J, Dufour-Rainfray D, Engelborghs S, Esselmann H, Fogli A, Gabelle A, Galloni E, Gondolf C, Grandhomme F, Grau-Rivera O, Hart M, Ikeuchi T, Jeromin A, Kasuga K, Keshavan A, Khalil M, Koertvelyessy P, Kulczynska-Przybik A, Laplanche JL, Lewczuk P, Li QX, Lleo A, Malaplate C, Marquie M, Masters CL, Mroczko B, Nogueira L, Orellana A, Otto M, Oudart JB, Paquet C, Paoletti FP, Parnetti L, Perret-Liaudet A, Peoc'H K, Poesen K, Puig-Pijoan A, Quadrio I, Quillard-Muraine M, Rucheton B, Schraen S, Schott JM, Shaw LM, Suarez-Calvet M, Tsolaki M, Tumani H, Udeh-Momoh CT, Vaudran L, Verbeek MM, Verde F, Vermunt L, Vogelgsang J, Wiltfang J, Zetterberg H, Lehmann S (2021)
Publication Type: Journal article
Publication year: 2021
DOI: 10.1002/alz.12545
Introduction: The current practice of quantifying cerebrospinal fluid (CSF) biomarkers as an aid in the diagnosis of Alzheimer's disease (AD) varies from center to center. For a same biochemical profile, interpretation and reporting of resultsmay differ, which can lead tomisunderstandings and raises questions about the commutability of tests.
APA:
Delaby, C., Teunissen, C.E., Blennow, K., Alcolea, D., Arisi, I., Amar, E.B.,... Lehmann, S. (2021). Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimers & Dementia. https://doi.org/10.1002/alz.12545
MLA:
Delaby, Constance, et al. "Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview." Alzheimers & Dementia (2021).
BibTeX: Download